Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system

European Journal of Clinical Pharmacology

Volumn 53, Issue 3-4, 1997, Pages 163-169

  Stahl, M M S ^a,e   Lindquist, M ^b   Pettersson, M ^b   Edwards, I R ^b   Sanderson, J H ^c   Taylor, N F A ^c   Fletcher, A P ^c   Schou, J S ^d  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b WHO Collaborating Ctr Intl Drug M   (Sweden)

^c IMS International   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Pharmacia & Upjohn AB   (Sweden)

Author keywords

Adverse drug reactions; Selective serotonin re uptake inhibitors

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADVERSE DRUG REACTION; AGGRESSION; AGITATION; ANXIETY; ARTICLE; CONVULSION; DEPRESSION; DRUG WITHDRAWAL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; STATISTICS; SWEATING; SYMPTOM; TREMOR; VERTIGO; WITHDRAWAL REFLEX; WITHDRAWAL SYNDROME; WORLD HEALTH ORGANIZATION;

1-NAPHTHYLAMINE; ADVERSE DRUG REACTION REPORTING SYSTEMS; FEMALE; FLUOXETINE; HUMANS; MALE; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SUBSTANCE WITHDRAWAL SYNDROME; WORLD HEALTH ORGANIZATION;

EID: 0031459202     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050357     Document Type: Article

References (36)

1. Lejoyeux M, Adès J. Mourad I, Solomon J, Dilsaver S (1996) Antidepressant withdrawal syndrome. Recognition, prevention and management. CNS Drugs 5: 278-292
2. Richelson E (1994) Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc 69: 1069-1081
3. Koopowitz LF, Berk M (1995) Paroxetine induced withdrawal effects. Hum Psychopharmacol 10: 147-148
4. Phillips SD (1995) A possible paroxetine withdrawal syndrome. Am J Psychiatry 152: 645-646
5. Pyke RE (1995) Paroxetine withdrawal syndrome. Am J Psychiatry 152: 149-150
6. Debattista C, Schatzberg AF (1995) Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry 152: 1235-1236
7. Fava GA, Grandi S (1995) Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol 15: 374-375
8. Bloch M, Stager SV, Braun AR, Rubinow DR (1995) Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet 346: 57
9. Frost L, Lal S (1995) Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry 152: 810
10. Dominguez RA, Goodnick PJ (1995) Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 15: 778-780
11. Barr LC, Goodman WK, Price LH (1994) Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry 151: 289
12. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA (1994) Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 14: 206-207
13. D'Arcy PF (1993) Dystonia and withdrawal symptoms with paroxetine. [letter] Int Pharm J 7: 140
14. Berlin CS (1996) Fluoxetine withdrawal symptoms. J Clin Psychiatry 57: 93-94
15. Einbinder E (1995) Fluoxetine withdrawal? Am J Psychiatry 152: 1235
16. Kasantikul D (1995) Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thailand 78: 53-54
17. Stoukides JA, Stoukides CA (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry 148: 1263
18. Louie AK, Lannon RA, Ajari LJ (1994) Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 151: 450-451
19. Rosenstock HA (1996) Sertraline withdrawal in two brothers: a case report. Int Clin Psychopharmacol 11: 58-59
20. Amsden GW, Georgian F (1996) Orthostatic hypotension induced by sertraline withdrawal. Pharmacotherapy 16: 684-686
21. Leiter FL, Nierenberg AA, Sanders KM, Stern TA (1995) Discontinuation reactions following sertraline. Biol Psychiatry 38: 694-695
22. Mallya G, White K, Gunderson C (1993) Is there a serotonergic withdrawal syndrome? Biol Psychiatry 33: 851-852
23. Szabadi E (1992) Fluvoxamine withdrawal syndrome. Br J Psychiatry 160: 283-284
24. Committee on Safety of Medicines and Medicines Control Agency (1993) Dystonia and withdrawal symptoms with paroxetine (Seroxat). Curr Probl Pharmacovigilance 19: 1
25. Ansseau M (1992) The Atlantic gap: clinical trials in Europe and the United States. Biol Psychiatry 31: 109-111
26. Black DW, Wesner R, Gabel J (1993) The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 54: 146-149
27. Kreider MS, Bushnell WD, Oakes R, Wheadon DE (1995) A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. J Clin Psychiatry 56: 142-145
28. Stein MB, Chartier MJ, Hazen AL, Kroft CDL, Chale RA. Coté D, Walker JR (1996) Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 16: 218-222
29. Inman W, Kubota K, Pearce G, Wilton L (1993) PEM report number 6. Paroxetine. Pharmacoepidemiol Drug Safety 2: 393-422
30. Goodnick PJ (1994) Pharmacokinetic optimization of therapy with newer antidepressants. Clin Pharmacokinet 27: 307-330
31. Stanford SC (1996) Prozac: panacea or puzzle? Trends Pharmacol Sci 17: 150-154
32. Richelson E (1996) Synaptic effects of antidepressants. J Clin Psychopharmacol 16 [Suppl 2]: 1S-9S
33. Proudfoot AT, Vale JA, Pesticides (1996) In: Weatherall DJ, Ledingham JGG, Warrell DA (eds) Oxford textbook of medicine. Oxford university press, Oxford, pp 1120-1124
34. Bolden-Watson C, Richelson E (1993) Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52: 1023-1029
35. Brodribb TR, Downey M, Gilbar PJ (1994) Efficacy and adverse effects of moclobemide. Lancet 343: 475
36. Baldessarini RJ (1995) Drugs and the treatment of psychiatric disorders. Depression and mania. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds) Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 431-459